Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A Phase 2B, 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to
Evaluate the Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH)
Inhibitor PF-04457845 in Adults with DSM-5 Current Cannabis Use Disorder (CUD)
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Collaborators:
Columbia University Johns Hopkins University Medical University of South Carolina National Institute on Drug Abuse (NIDA)